SIGLEC9 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL7090658	0.61	2/20
SCHEMBL1876139	0.57	2/20
SCHEMBL31023936	0.57	2/20
SCHEMBL23013331	0.57	2/20
SCHEMBL23013515	0.57	2/20
SCHEMBL15379817	0.56	2/20
SCHEMBL6345789	0.55	2/20
SCHEMBL27717981	0.54	2/20
SCHEMBL2963238	0.53	2/20
SCHEMBL23022524	0.53	2/20
SCHEMBL23022526	0.53	2/20
SCHEMBL23022528	0.53	2/20
SCHEMBL29485608	0.53	2/20
SCHEMBL29485617	0.53	2/20
SCHEMBL28306630	0.52	2/20
SCHEMBL25803083	0.51	2/20
SCHEMBL11447303	0.51	2/20
SCHEMBL6343306	0.51	2/20
SCHEMBL6346829	0.51	2/20
SCHEMBL6346302	0.50	2/20

Clinical trials — most relevant to SIGLEC9 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy	PHASE4	UNKNOWN
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation	PHASE3	UNKNOWN
Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)	PHASE1/PHASE2	UNKNOWN
Daratumumab in Combination With ATRA	PHASE1/PHASE2	COMPLETED
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia	PHASE1/PHASE2	RECRUITING
GD2/CD56 Bi-specific CAR-T Cell Therapy	PHASE1/PHASE2	RECRUITING
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment	PHASE2	UNKNOWN
Multiple CAR-T Cell Therapy Targeting AML	PHASE1/PHASE2	RECRUITING
A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis	PHASE2	COMPLETED
TOLERA: Tolerance Enhancement in RA	PHASE2	UNKNOWN
The Phase I Study of SIG001 Antibody on Cancer Therapy.	PHASE1	NOT_YET_RECRUITING
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection	PHASE1	UNKNOWN
Universal CAR-T Cells Targeting AML	PHASE1	RECRUITING
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	COMPLETED
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies	EARLY_PHASE1	UNKNOWN
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies	EARLY_PHASE1	UNKNOWN
Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies	EARLY_PHASE1	UNKNOWN
Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis	nan	UNKNOWN
Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease	nan	COMPLETED
Galectin-3 Binding Protein in Cardiovascular Disease and Chronic Heart Failure	nan	COMPLETED
Proteomics & Glyco-Proteomic Analysis of Follicular Fluid	nan	UNKNOWN
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes	nan	COMPLETED
Don't Eat me Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.	nan	UNKNOWN
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program	nan	COMPLETED
Study on the Correlation Between Serum and Fecal Sialic Acid Levels and Tumor Characteristics as Well as Postoperative Anastomotic Leakage in Patients With Colorectal Tumors	nan	NOT_YET_RECRUITING
Measuring Immune Tolerance to Predict Miscarriage or Failed Embryo Transfer	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors	nan	NOT_YET_RECRUITING
sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SIGLEC9 binder may also engage these)

Protein	Name	Similarity
Q95LH0	—	1.000	Q95LH0 →
O43699	—	1.000	O43699 →
Q9NYZ4	—	0.999	Q9NYZ4 →
SIGLEC7	Sialic acid-binding Ig-like lectin 7	0.998	landscape →
Q96PQ1	—	0.997	Q96PQ1 →
A6NMB1	—	0.994	A6NMB1 →
Q64JA4	—	0.991	Q64JA4 →
Q91Y57	—	0.991	Q91Y57 →
Q6DN72	—	0.990	Q6DN72 →
Q920G3	—	0.988	Q920G3 →
P20138	—	0.988	P20138 →
Q80ZE3	—	0.987	Q80ZE3 →
Q96RL6	—	0.985	Q96RL6 →
Q08ET2	—	0.984	Q08ET2 →
O15389	—	0.983	O15389 →
Q96LC7	—	0.982	Q96LC7 →
Q8R4Y0	—	0.980	Q8R4Y0 →
P43630	—	0.978	P43630 →
Q28125	—	0.976	Q28125 →
Q96PJ5	—	0.974	Q96PJ5 →
P43629	—	0.973	P43629 →
Q9HBG7	—	0.972	Q9HBG7 →
Q8MJZ7	—	0.972	Q8MJZ7 →
Q8TDQ1	—	0.972	Q8TDQ1 →
Q7TSN2	—	0.972	Q7TSN2 →
Q8NHK3	—	0.972	Q8NHK3 →
Q63994	—	0.971	Q63994 →
Q99706	—	0.971	Q99706 →
B6A8C7	—	0.971	B6A8C7 →
Q96A28	—	0.971	Q96A28 →